New oral drug tested for blood cancers in first human study
NCT ID NCT05728658
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-phase trial is testing an experimental drug called ICP-248, taken as a pill, for people with certain B-cell blood cancers like leukemia and lymphoma. The study will enroll about 191 adults and aims to find the safest dose and see if the drug works alone or with another drug, orelabrutinib. The main goals are to check safety and measure how the body processes the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
Contact
-
Hematology Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
Contact
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
Contact
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
Contact
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, Jiangxi, 330029, China
Contact
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100191, China
Contact
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact
-
Shandong cancer hospital
RECRUITINGJinan, Shandong, 250117, China
Contact
-
Shenyang Hospital Of China Medical University
RECRUITINGShenyang, Liaoning, 110022, China
Contact
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510062, China
Contact
-
The Central Hospital of Wuhan
RECRUITINGWuhan, Hubei, 430014, China
Contact
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230022, China
Contact
-
The First Affiliated Hospital of Bengbu Medical College
RECRUITINGBengbu, Anhui, 233099, China
Contact
-
The First Affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, 400016, China
Contact
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330000, China
Contact
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361003, China
Contact
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450008, China
Contact
-
The Second Hospital of Dalian Medical University
RECRUITINGDalian, Liaoning, 116027, China
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610000, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ICP-248 (an experimental oral drug) alone or combined with orelabrutinib
What this could lead to
If successful, this could point toward a new treatment option for certain blood cancers like leukemia and lymphoma.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and results may not lead to a usable therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.